2023年07月31日 21時00分

Source: China Medical System Holdings Ltd.

China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management

SHENZHEN, CHINA, 2023年07月31日 - (JCN Newswire) - Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.

MSCI is one of the most widely used, influential, and referenced rating companies in the global market. Based on a scientifically rigorous evaluation system, it evaluates companies' risk control performance and sustainable development potential comprehensively from various aspects such as environment, human capital, health accessibility, product safety and quality, and corporate governance. MSCI-ESG rating results have been regarded by global investors as an important non-financial basis for investment decision-making. Being back to the "AA" rating, reflects the full recognition of the Group's ESG management practices by the international authoritative rating company.

The Group deeply integrates the concept of sustainable development into its operations with a development perspective, continuously improves its internal governance under the guidance of its ESG strategy, and actively assumes its responsibilities as a corporate citizen. Based on years of continuous investment in sustainable development, CMS's ESG management has been widely recognized: over the past three years, the Group's MSCI-ESG rating has maintained an "A" or "AA; its S&P Global ESG score surpassed 92% of the global peers with a score of 53, and successfully stood out from approximately 1,600 Chinese companies to be included in the first "Sustainability Yearbook (China)" of S&P Global.

In the future, CMS will always keep in mind its mission of being a responsible citizen, and work together with its stakeholders to promote healthy, harmonious, and sustainable development of the industry, society, and environment.

About CMS:

CMS (0867.HK) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs.

CMS focuses on developing first- or best-in-class innovative products and has made the layout of 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group.

Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

Source: China Medical System Holdings Ltd.
セクター: ヘルスケア, メドテック

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

関連プレスリリース


China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
2024年06月18日 19時53分
 
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
2024年04月23日 23時06分
 
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
2024年04月01日 21時30分
 
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
2024年03月28日 11時29分
 
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
2024年02月04日 10時00分
 
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
2024年01月02日 15時00分
 
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
2023年12月13日 18時36分
 
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
2023年08月24日 21時00分
 
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
2023年06月12日 21時00分
 
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
2023年05月30日 23時00分
 
もっと見る >>

新着プレスリリース


もっと見る >>